Search
Clinafloxacin
go.drugbank.com/drugs/DB14025ExperimentalIt has been proven to present good antibiotic properties. However, its approval and release have been halted due to the presence of serious side effects.
Zinpentraxin alfa
go.drugbank.com/drugs/DB14852InvestigationalIt is under investigation in clinical trial NCT01981850 (A Phase 2 Study Of PRM-151 In Subjects With Myelofibrosis).
MT-0169
go.drugbank.com/drugs/DB17430InvestigationalMT-0169 is a usion protein comprised of an enzymatically active Shiga-like toxin-I A1 subunit fused to a human single chain variable fragment with affinity for human CD38 cell surface protein.
Ligufalimab
go.drugbank.com/drugs/DB17542InvestigationalIt is under investigation in clinical trial NCT04900350 (A Trial of AK117 (Anti-cd47) in Patients With Myelodysplastic Syndrome).
TT 173
go.drugbank.com/drugs/DB17717InvestigationalTT 173 is a Modified Human Tissue Factor currently being investigated to treat bleeding disorders such as hemophilia and von Willebrand disease, as well as bleeding episodes in cutaneous injuries or dental
Exbivirumab
go.drugbank.com/drugs/DB17747ExperimentalIt is one of the active ingredients in HepeX-B, a drug product containing two human monoclonal antibodies to the hepatitis B virus (HBV) surface antigen.[A259202]
AMP-101
go.drugbank.com/drugs/DB18253ExperimentalIt is under investigation for the treatment of Dok-7-associated myasthenia.
Setiptiline
go.drugbank.com/drugs/DB09304ExperimentalSetiptiline is a tetracyclic antidepressant (TeCA) which acts as a noradrenergic and specific serotonergic antidepressant (NaSSA). In Japan, the company Mochida started its commercialization for the treatment of depression started in 1989.
Sodium copper chlorophyllin
go.drugbank.com/drugs/DB16522InvestigationalSodium copper chlorophyllin (SCC) is a water-soluble and bright green mixture derived from natural chlorophyll that has potential antimutagenic and antioxidant properties . This compound is used as a food colorant and supplement . SCC of...
Apadenoson
go.drugbank.com/drugs/DB05009InvestigationalIt is developed by Bristol-Myers Squibb and is in phase II of clinical trials.